CLEARLY
BRUKINSA to help you take
control of your FL

National Comprehensive Cancer Network® (NCCN®) recommended

The National Comprehensive Cancer Network® (NCCN®) recommends zanubrutinib (BRUKINSA®), in combination with obinutuzumab, as an NCCN Category 2A treatment option for people with FL who have received at least two prior treatments.*

NCCN is a not-for-profit alliance of 33 leading cancer centers in the United States devoted to patient care, research, and education. The organization creates cancer guidelines that are considered the standard to guide treatment decisions.

* Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 18, 2025. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

How does BRUKINSA work?

BRUKINSA, also known as zanubrutinib, is a type of targeted treatment known as a BTK inhibitor because it works to shut down (or inhibit) a protein within cancerous B cells called Bruton’s tyrosine kinase (BTK). Shutting down BTK is important because this protein sends non-stop signals within cancerous B cells, such as those that cause follicular lymphoma (FL), to grow and spread.
BRUKINSA pronunciation (BROO-kin-sah)
Zanubrutinub pronunciation (zan-oo-BROO-ti-nib)
What makes BRUKINSA different
Every treatment option is different. Knowing the differences can help you take an active role in discussing treatment options with your doctor.

BRUKINSA is a treatment option for follicular lymphoma (FL)

BRUKINSA is the first and only BTK inhibitor approved for the treatment of FL. For FL, BRUKINSA is taken with obinutuzumab, a monoclonal antibody (mAB) used to treat different lymphomas.

BRUKINSA has been approved in other lymphomas, including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and Waldenström’s macroglobulinemia (WM), as well as patients with mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) who have received prior treatment.

Blocks up to 100% of BTK

BRUKINSA was designed to block BTK signaling and keep it shut down for 24 hours. This may help stop the signaling in cancerous B cells.

  • BRUKINSA has been shown to block 100% of BTK in blood cells and 94% to 100% of BTK in lymph nodes when taken at the recommended total daily dose of 320 mg. The significance of blocking up to 100% of BTK on treatment responses has not been established

Significantly more patients taking BRUKINSA + obinutuzumab saw an improvement in their FL than with obinutuzumab alone

In a clinical study comparing FL treatment options, BRUKINSA + obinutuzumab was shown to be more effective than obinutuzumab. Three types of responses were studied: overall response rate (ORR), duration of response (DOR), and progression-free survival (PFS).

Explore BRUKINSA efficacy for patients with FL who have received at least 2 prior treatments.

Side effects for BRUKINSA + obinutuzumab were similar to those seen for BRUKINSA and obinutuzumab separately

Patients who took BRUKINSA + obinutuzumab experienced side effects that were comparable to those seen for BRUKINSA and obinutuzumab separately.

BRUKINSA is an oral treatment, and obinutuzumab is an intravenous infusion

BRUKINSA is an oral treatment that can be prescribed on a dosing schedule that meets your needs.

  • BRUKINSA can be taken either once daily (2 tablets) or twice daily (1 tablet in the morning and 1 tablet later in the day). Talk to your doctor about which dosing schedule is best for you
  • BRUKINSA can be taken at home

BRUKINSA must be taken with obinutuzumab for FL. Obinutuzumab is an intravenous infusion given in cycles that must be administered at a clinic or infusion center. Your doctor will talk to you about the infusion schedule for obinutuzumab.

LEARN MORE ABOUT BRUKINSA EFFICACY AND SAFETY IN FL

What is FL?

FL is a form of non-Hodgkin’s lymphoma that arises from abnormal B cells (also known as B lymphocytes). B cells are a type of white blood cell found in your blood, lymph nodes, and bone marrow. When B cells develop normally, they help protect the body from infection and disease.

In FL, abnormal B cells are found mostly in lymph nodes and may spread to the bone marrow or spleen.

Normal cells vs FL cancer cells

For those taking BRUKINSA and their caregivers, myBeOne Support™ program logo is here to help

The myBeOne Support program pairs eligible patients with a dedicated Oncology Nurse Advocate who can help personalize support throughout your treatment with BRUKINSA.

Call 1-833-234-4363 Monday through Friday, 8 AM to 8 PM Eastern Time to speak with an Oncology Nurse Advocate today.

VISIT myBeOneSupport.com TO LEARN MORE

myBeOneSupport™ is not insurance and does not guarantee product coverage or reimbursement.

IMPORTANT SAFETY INFORMATION

What should I tell my healthcare provider before taking BRUKINSA?

Before taking BRUKINSA, tell your healthcare provider about all of your medical conditions, including if you:

  • have bleeding problems.
  • have had recent surgery or plan to have surgery. Your healthcare provider may stop BRUKINSA for any planned medical, surgical, or dental procedure.
  • have an infection.
  • have or had heart rhythm problems.
  • have high blood pressure.
  • have liver problems, including a history of hepatitis B virus (HBV) infection.
  • are pregnant or plan to become pregnant. BRUKINSA can harm your unborn baby. If you are able to become pregnant, your healthcare provider may do a pregnancy test before starting treatment with BRUKINSA.
    1. Females should avoid getting pregnant during treatment and for 1 week after the last dose of BRUKINSA. You should use effective birth control (contraception) during treatment and for 1 week after the last dose of BRUKINSA.
    2. Males should avoid getting female partners pregnant during treatment and for 1 week after the last dose of BRUKINSA. You should use effective birth control (contraception) during treatment and for 1 week after the last dose of BRUKINSA.
  • are breastfeeding or plan to breastfeed. It is not known if BRUKINSA passes into your breast milk. Do not breastfeed during treatment with BRUKINSA and for 2 weeks after the last dose of BRUKINSA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking BRUKINSA with certain other medications may affect how BRUKINSA works and can cause side effects.

What are the possible side effects of BRUKINSA?

BRUKINSA may cause serious side effects, including:

  • Bleeding problems (hemorrhage). Bleeding problems are common with BRUKINSA, and can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including:
    1. blood in your stools or black stools (looks like tar)
    2. pink or brown urine
    3. unexpected bleeding, or bleeding that is severe or you cannot control
    4. vomit blood or vomit that looks like coffee grounds
    5. cough up blood or blood clots
    6. increased bruising
    7. dizziness
    8. weakness
    9. confusion
    10. change in speech
    11. headache that lasts a long time
  • Infections that can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, or flu-like symptoms.
  • Decrease in blood cell counts (white blood cells, platelets, and red blood cells). Your healthcare provider should do blood tests during treatment with BRUKINSA to check your blood counts.
  • Second primary cancers. New cancers have happened in people during treatment with BRUKINSA, including cancers of the skin or other organs. Your healthcare provider will check you for other cancers during treatment with BRUKINSA. Use sun protection when you are outside in sunlight.
  • Heart rhythm problems (atrial fibrillation, atrial flutter, and ventricular arrhythmias) that can be serious and may lead to death. Tell your healthcare provider if you have any of the following signs or symptoms:
    1. your heartbeat is fast or irregular
    2. feel lightheaded or dizzy
    3. pass out (faint)
    4. shortness of breath
    5. chest discomfort
  • Liver problems. Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with BRUKINSA. Your healthcare provider will do blood tests to check your liver before and during treatment with BRUKINSA. Tell your healthcare provider or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes.

The most common side effects of BRUKINSA include:

  • decreased white blood cell count
  • decreased platelet count
  • upper respiratory tract infection
  • bleeding
  • muscle, bone, or joint pain

These are not all the possible side effects of BRUKINSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is BRUKINSA?

BRUKINSA is a prescription medicine used to treat adults with:

  • Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Waldenström’s macroglobulinemia (WM).
  • Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
  • Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.
  • Follicular lymphoma (FL), in combination with the medicine obinutuzumab, when the disease has come back or did not respond to treatment and who have received at least two prior treatments.

It is not known if BRUKINSA is safe and effective in children.

Please see full Prescribing Information including Patient Information.